Bristol-Myers Squibb Stock News

The Undercovered Dozen series spotlights 12 lesser-known stocks highlighted in recent Seeking Alpha articles. This week's edition covers articles published between October 10 and October 16, offering fresh investment ideas. The series aims to inspire discussion and help investors discover overlooked opportunities in the market.

REDMOND, Wash. and PRINCETON, N.J.

Bristol Myers Squibb remains undervalued, ranking 12th on my Magic Formula screen with strong earnings yield and capital returns amongst the S&P 500. Company pivoting from small-molecule drugs to mRNA and gene therapies via BioNTech partnership and Orbital Therapeutics acquisition. Growth portfolio offsetting legacy drug declines, but key patents like Eliquis and Opdivo face expirations by 2028.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ESMO--Bristol Myers Squibb to Present Data at ESMO® 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types.

REDMOND, Wash. , Oct. 13, 2025 /PRNewswire/ -- SystImmune, Inc., a clinical-stage biotechnology company, today announced the treatment of the first patient in the IZABRIGHT-Breast01 study (NCT06926868), a global Ph2/3 registrational study of izalontamab brengitecan (iza-bren) in previously untreated triple negative breast cancer ineligible for anti-PD(L)1 drugs.

Fourteen of the highest-yielding, 'safer' S&P 500 dividend stocks are currently attractively priced, with free cash flow supporting their payouts. Top ten S&P 500 dividend 'dogs' are projected to deliver 23.93% to 38.57% net gains by October 2026, based on analyst targets. Stocks like CAG, VZ, DOC, BMY, KVUE, CPB, UDR, VTRS, KIM, TFC, KEY, HPQ, T, and RF meet the ideal of dividends from $1K inv...

Bristol Myers Squibb offers a compelling value entry for long-term income investors, despite looming patent cliffs and execution risks. BMY's growth portfolio is positioned to offset revenue losses from Eliquis and Opdivo expirations, supporting a moderate long-term revenue CAGR. Current valuations reflect excessive pessimism, trading at a 25% discount to BMY's five-year average, with downside ...

Drugmaker Bristol Myers Squibb said on Friday it will acquire privately held cell therapy developer Orbital Therapeutics for $1.5 billion in cash.